ALL CANCER TYPES
EAY131: (MATCH) Molecular Analysis for Therapy Choice
Breast Cancer Clinical Trials:
A011202: A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
BCCR: Breast Cancer Collaborative Registry (Non-treatment study)
EAZ171: Prospective validation trial of taxanes therapy (docetaxel or weekly paclitaxel) and risk of chemotherapy-induced peripheral neuropathy in African American women
EPIK-B3: A Phase III, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with nab-paclitaxel in patients with advanced triple negative breast cancer with either phosphoinositide-3-kinase catalytic subunit alpha (PIK3CA) nutation or phosphatase and tensin homolog protein (PTEN) loss without PIK3CA mutation
Alliance A191901: Optimizing Endocrine Therapy Through Motivational Interviewing and Test Interventions
Colorectal:
Alliance A021703: Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation In Patients With Previously Untreated Metastatic Colorectal Cancer (SOLARIS)
Hematological Malignancies:
Connect MDS/AML: A Registry for Newly Diagnosed MDS and AML Patients
Lung Cancer Clinical Trials:
Alliance A081801: Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)
A151216: (ALCHEMIST) Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial
ECOG E4512: A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib vs. Placebo for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
LUNGMAP: A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer
KEYNOTE-867: A Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiotherapy (SBRT) with or without Pembrolizumab (MK-347) in Participants with Medically Inoperable Stages I or IIA NSCLC
Alliance A171901: Older Non-Small Cell Lung Cancer Patients (>/= 70 Years of Age) Treated with First-Line MK-3475 (Pembrolizumab) +/- Chemotherapy (Oncologist’s/Patients Choice)
Website for all clinical trials: www.clinicaltrials.gov
For more information about ongoing clinical trials at the William E. Kahlert Regional Cancer Center, please contact the oncology research team at 410-601-6120